Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital()

BACKGROUND: Currently, biotherapy is mainly administered to treat patients with severe asthma with the Type 2 (T2) inflammation phenotype. The variability of T2 inflammatory markers remains poorly understood. OBJECTIVE: We aimed to describe the individual distributions of different biomarkers at var...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongwen, Zhang, Qing, Wang, Jingru, Gao, Shengnan, Li, Chunxiao, Wang, Jianxin, Zhang, Shuhua, Lin, Jiangtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463912/
https://www.ncbi.nlm.nih.gov/pubmed/34611471
http://dx.doi.org/10.1016/j.waojou.2021.100547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463912/
https://www.ncbi.nlm.nih.gov/pubmed/34611471
http://dx.doi.org/10.1016/j.waojou.2021.100547

Ejemplares similares